{
 "ticker": "WDNA",
 "name": "WisdomTree BioRevolution Fund",
 "issuer": "WisdomTree",
 "desk": "themes",
 "url": "https://etfiq.com/funds/WDNA",
 "html": "https://etfiq.com/funds/WDNA",
 "markdown": "https://etfiq.com/funds/WDNA.md",
 "as_of": "2026-09-11",
 "verdict": "WDNA holds 80 stocks, and 74% of its weight is outside the S&P 500.",
 "key_facts": [
  {
   "key": "already_in_the_s_p_500",
   "label": "Already in the S&P 500",
   "value": "25.9%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "WDNA, already in the S&P 500: 25.9%, as of Sep 11, 2026."
  },
  {
   "key": "active_share_vs_the_s_p_500",
   "label": "Active share vs the S&P 500",
   "value": "95.3%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "WDNA, active share vs the S&P 500: 95.3%, as of Sep 11, 2026."
  },
  {
   "key": "top_ten_holdings",
   "label": "Top ten holdings",
   "value": "30.7%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "WDNA, top ten holdings: 30.7%, as of Sep 11, 2026."
  },
  {
   "key": "total_return_1_year",
   "label": "Total return, 1 year",
   "value": "+56.1%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "WDNA, total return, 1 year: +56.1%, as of Sep 11, 2026."
  },
  {
   "key": "net_assets",
   "label": "Net assets",
   "value": "$3m",
   "source": "SEC filing, whole fund, as filed for Jun 30, 2026",
   "as_of": "2026-09-11",
   "sentence": "WDNA, net assets: $3m (SEC filing, whole fund, as filed for Jun 30, 2026)."
  },
  {
   "key": "expense_ratio",
   "label": "Expense ratio",
   "value": "0.45%",
   "source": "485BPOS XBRL, Oct 28, 2025",
   "as_of": "2026-09-11",
   "sentence": "WDNA, expense ratio: 0.45% (485BPOS XBRL, Oct 28, 2025)."
  }
 ],
 "fields": [
  {
   "key": "theme",
   "label": "Theme",
   "value": "Healthcare innovation and GLP-1",
   "source": "ETFIQ, editorial"
  },
  {
   "key": "launched",
   "label": "Launched",
   "value": "Jun 3, 2021",
   "source": null
  },
  {
   "key": "already_in_the_s_p_500_by_weight",
   "label": "Already in the S&P 500, by weight",
   "value": "25.9%",
   "source": "ETFIQ"
  },
  {
   "key": "active_share_vs_the_s_p_500",
   "label": "Active share vs the S&P 500",
   "value": "95.3%",
   "source": "ETFIQ"
  },
  {
   "key": "already_in_the_nasdaq_100_by_weight",
   "label": "Already in the Nasdaq-100, by weight",
   "value": "5.8%",
   "source": "ETFIQ"
  },
  {
   "key": "active_share_vs_the_nasdaq_100",
   "label": "Active share vs the Nasdaq-100",
   "value": "97.4%",
   "source": "ETFIQ"
  },
  {
   "key": "top_ten_holdings_weight",
   "label": "Top ten holdings weight",
   "value": "30.7%",
   "source": null
  },
  {
   "key": "holdings",
   "label": "Holdings",
   "value": "80",
   "source": null
  },
  {
   "key": "holdings_as_of",
   "label": "Holdings as of",
   "value": "Jun 30, 2026",
   "source": "SEC N-PORT"
  },
  {
   "key": "top_holdings",
   "label": "Top holdings",
   "value": "TWIST BIOSCIENCE CORP 6.0%, MODERNA INC 4.2%, ELI LILLY & COMPANY 4.1%, JOHNSON & JOHNSON 3.0%, UNITED THERAPEUTICS CORP 2.5%, NATERA INC 2.3%, TEMPUS AI INC 2.3%, IMMUNOME INC 2.3%, STRUCTURE THERAPEUTICS INC 2.1%, STOKE THERAPEUTICS INC 2.1%",
   "source": null
  },
  {
   "key": "net_assets",
   "label": "Net assets",
   "value": "$3m",
   "source": "SEC filing, whole fund, as filed for Jun 30, 2026"
  },
  {
   "key": "below_its_all_time_high",
   "label": "Below its all-time high",
   "value": "\u221215.5%",
   "source": "ETFIQ"
  },
  {
   "key": "expense_ratio",
   "label": "Expense ratio",
   "value": "0.45%",
   "source": "485BPOS XBRL, Oct 28, 2025"
  },
  {
   "key": "fee_for_the_part_that_differs_from_the_s_p_500_active_expense_ratio",
   "label": "Fee for the part that differs from the S&P 500, active expense ratio",
   "value": "0.47%",
   "source": "ETFIQ"
  },
  {
   "key": "closest_funds_by_holdings_overlap",
   "label": "Closest funds by holdings overlap",
   "value": "GNOM 35%, HELX 34%, IBBQ 28%, ARKG 27%, BBP 26%",
   "source": null
  }
 ],
 "periods": [
  {
   "window": "3 months",
   "Total return": "+22.9%",
   "S&P 500": "+3.3%",
   "Gap to S&P 500": "+19.6 pts",
   "Gap to Nasdaq-100": "+23.7 pts"
  },
  {
   "window": "6 months",
   "Total return": "+29.6%",
   "S&P 500": "+16.0%",
   "Gap to S&P 500": "+13.6 pts",
   "Gap to Nasdaq-100": "+8.9 pts"
  },
  {
   "window": "1 year",
   "Total return": "+56.1%",
   "S&P 500": "+17.5%",
   "Gap to S&P 500": "+38.6 pts",
   "Gap to Nasdaq-100": "+33.2 pts"
  },
  {
   "window": "3 years",
   "Total return": "+44.0%",
   "S&P 500": "+77.9%",
   "Gap to S&P 500": "\u221233.9 pts",
   "Gap to Nasdaq-100": "\u221251.1 pts"
  },
  {
   "window": "Since launch",
   "Total return": "\u22125.5%",
   "S&P 500": "+96.0%",
   "Gap to S&P 500": "\u2212101.5 pts",
   "Gap to Nasdaq-100": "\u2212129.0 pts"
  }
 ],
 "questions": [
  {
   "q": "How much of WDNA is in S&P 500 companies?",
   "a": "By its holdings filed for Jun 30, 2026, 26% of WDNA by weight is stocks the S&P 500 already holds. Its active share against the index is 95%, so that share is the part doing something different."
  },
  {
   "q": "What does WDNA hold?",
   "a": "80 positions as filed for Jun 30, 2026, with the top ten at 31% of the fund. The largest are TWIST BIOSCIENCE CORP at 6.0%, MODERNA INC at 4.2%, ELI LILLY & COMPANY at 4.1%."
  },
  {
   "q": "Has WDNA beaten the S&P 500?",
   "a": "Over the year to Sep 11, 2026 WDNA returned +56.1% with distributions reinvested, against +17.5% for the S&P 500, so it finished ahead of the index by 38.6 points."
  },
  {
   "q": "What does WDNA cost?",
   "a": "The prospectus expense ratio is 0.45% a year. Because 95% of the fund differs from the S&P 500, the fee on that differing part works out at 0.47%."
  }
 ],
 "generated": "2026-09-13",
 "license": "Free to use with attribution. ETFIQ (etfiq.com)."
}